Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ferric Maltol
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The commercial stage pharmaceutical company focused on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol) confirmed to investors that the TGA has registered Feraccru® as a treatment in the Australian Register of Thera...
Brand Name : Feraccru
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 09, 2021
Lead Product(s) : Ferric Maltol
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ferric oxide adipate
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Shield Therapeutics PT20 Paper Publication
Details : PT20 is a novel iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia (when there is too much phosphorus present in the blood) related to dialysis or non-dialysis dependent chronic kidney disease (CKD).
Brand Name : PT20
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 16, 2020
Lead Product(s) : Ferric oxide adipate
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ferric Maltol
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Beijing Aosaikang Pharmaceutical
Deal Size : $62.8 million
Deal Type : Licensing Agreement
China licence agreement for Feraccru/Accrufer
Details : Shield Therapeutics enters into an exclusive licence agreement for its lead product Feraccru®/Accrufer® with Beijing Aosaikang Pharmaceutical Co. Ltd. .
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $11.4 million
January 08, 2020
Lead Product(s) : Ferric Maltol
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Beijing Aosaikang Pharmaceutical
Deal Size : $62.8 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?